Literature DB >> 20178980

cAMP/CREB-mediated transcriptional regulation of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) expression.

Hui Liao1, Matthew C Hyman, Amy E Baek, Keigo Fukase, David J Pinsky.   

Abstract

CD39 is a transmembrane enzyme that inhibits platelet reactivity and inflammation by phosphohydrolyzing ATP and ADP to AMP. Cyclic AMP (cAMP), an essential second messenger, is particularly important in regulating genes controlling vascular homeostasis. These experiments test the hypothesis that cAMP might positively regulate the expression of CD39 and thereby modulate important vascular homeostatic properties. Cd39 mRNA was induced by 13.8- fold in RAW cells treated with a membrane-permeant cAMP analogue (8-bromo-cyclic AMP; 8-Br-cAMP), stimulation of adenylate cyclase, or prostanoids known to drive cAMP response. Fluorescence-activated cell sorting, immunofluorescence, and TLC assays demonstrated that both CD39 protein expression and enzymatic activity were increased in cells treated with 8-Br-cAMP but not in cells transfected with short hairpin RNA against CD39. This analogue drove a significant increase in transcriptional activity at the Cd39 promoter although not when the promoter's cAMP-response element sites were mutated. Pretreatment with cAMP-dependent protein kinase (PKA), phosphoinositide 3-kinase (PI3K), or ERK inhibitors nearly obliterated the cAMP-driven increase in Cd39 mRNA, protein expression, and promoter activity. 8-Br-cAMP greatly increased the phosphorylation of CREB1 (Ser(133)) and ATF2 (Thr(71)) in a PKA-, PI3K-, and ERK-dependent fashion. Chromatin immunoprecipitation assays demonstrated that binding of phosphorylated CREB1 and ATF2 to cAMP-response element-like sites was significantly increased with 8-Br-cAMP treatment and that binding was reduced with PKA, PI3K, and ERK inhibition, whereas transfection of Creb1 and Atf2 overexpression constructs enhanced cAMP-driven Cd39 mRNA expression. Transfection of RAW cells with mutated Creb1 (S133A) reduced cAMP-driven Cd39 mRNA expression. Furthermore, the cAMP-mediated induction of Cd39 mRNA, protein, and phosphohydrolytic activity was replicated in primary peritoneal macrophages. These data identify cAMP as a crucial regulator of macrophage CD39 expression and demonstrate that cAMP acts through the PKA/CREB, PKA/PI3K/ATF2, and PKA/ERK/ATF2 pathways to control a key vascular homeostatic mediator.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20178980      PMCID: PMC2863166          DOI: 10.1074/jbc.M110.116905

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

Review 1.  The MEK/ERK cascade: from signaling specificity to diverse functions.

Authors:  Yoav D Shaul; Rony Seger
Journal:  Biochim Biophys Acta       Date:  2006-10-19

2.  The p85 regulatory subunit of PI3K mediates TSH-cAMP-PKA growth and survival signals.

Authors:  G De Gregorio; A Coppa; C Cosentino; S Ucci; S Messina; A Nicolussi; S D'Inzeo; A Di Pardo; E V Avvedimento; A Porcellini
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

3.  Molecular regulation of the PAI-1 gene by hypoxia: contributions of Egr-1, HIF-1alpha, and C/EBPalpha.

Authors:  Hui Liao; Matthew C Hyman; Daniel A Lawrence; David J Pinsky
Journal:  FASEB J       Date:  2006-12-28       Impact factor: 5.191

4.  Assembly of a functional beta interferon enhanceosome is dependent on ATF-2-c-jun heterodimer orientation.

Authors:  J V Falvo; B S Parekh; C H Lin; E Fraenkel; T Maniatis
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

5.  CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness.

Authors:  Norikatsu Mizumoto; Tadashi Kumamoto; Simon C Robson; Jean Sévigny; Hiroyuki Matsue; Keiichi Enjyoji; Akira Takashima
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

6.  Multiple cAMP-induced signaling cascades regulate prolactin expression in T cells.

Authors:  S Gerlo; P Verdood; E L Hooghe-Peters; R Kooijman
Journal:  Cell Mol Life Sci       Date:  2006-01       Impact factor: 9.261

Review 7.  Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation.

Authors:  Philip J S Stork; John M Schmitt
Journal:  Trends Cell Biol       Date:  2002-06       Impact factor: 20.808

Review 8.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Authors:  Amancio Carnero; Carmen Blanco-Aparicio; Oliver Renner; Wolfgang Link; Juan F M Leal
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

9.  Phosphorylated CREB binds specifically to the nuclear protein CBP.

Authors:  J C Chrivia; R P Kwok; N Lamb; M Hagiwara; M R Montminy; R H Goodman
Journal:  Nature       Date:  1993-10-28       Impact factor: 49.962

10.  Down-regulation of the cyclin A promoter in differentiating human embryonal carcinoma cells is mediated by depletion of ATF-1 and ATF-2 in the complex at the ATF/CRE site.

Authors:  T Nakamura; S Okuyama; S Okamoto; T Nakajima; S Sekiya; K Oda
Journal:  Exp Cell Res       Date:  1995-02       Impact factor: 3.905

View more
  45 in total

1.  Human macrophage SCN5A activates an innate immune signaling pathway for antiviral host defense.

Authors:  Alexis Jones; Danielle Kainz; Faatima Khan; Cara Lee; Michael D Carrithers
Journal:  J Biol Chem       Date:  2014-11-03       Impact factor: 5.157

2.  Transgenic swine: expression of human CD39 protects against myocardial injury.

Authors:  Debra G Wheeler; Matthew E Joseph; Shouvik D Mahamud; William L Aurand; Peter J Mohler; Vincent J Pompili; Karen M Dwyer; Mark B Nottle; Sharon J Harrison; Anthony J F d'Apice; Simon C Robson; Peter J Cowan; Richard J Gumina
Journal:  J Mol Cell Cardiol       Date:  2012-01-12       Impact factor: 5.000

3.  Segregated regulatory CD39+CD4+ T cell function: TGF-β-producing Foxp3- and IL-10-producing Foxp3+ cells are interdependent for protection against collagen-induced arthritis.

Authors:  Irina Kochetkova; Theresa Thornburg; Gayle Callis; David W Pascual
Journal:  J Immunol       Date:  2011-10-03       Impact factor: 5.422

4.  The unfolded protein response and the phosphorylations of activating transcription factor 2 in the trans-activation of il23a promoter produced by β-glucans.

Authors:  Mario Rodríguez; Esther Domingo; Sara Alonso; Javier García Frade; José Eiros; Mariano Sánchez Crespo; Nieves Fernández
Journal:  J Biol Chem       Date:  2014-06-30       Impact factor: 5.157

Review 5.  Conversion of extracellular ATP into adenosine: a master switch in renal health and disease.

Authors:  Karen M Dwyer; Bellamkonda K Kishore; Simon C Robson
Journal:  Nat Rev Nephrol       Date:  2020-07-08       Impact factor: 28.314

6.  CD39 improves survival in microbial sepsis by attenuating systemic inflammation.

Authors:  Balázs Csóka; Zoltán H Németh; Gábor Törő; Balázs Koscsó; Endre Kókai; Simon C Robson; Keiichi Enjyoji; Rolando H Rolandelli; Katalin Erdélyi; Pál Pacher; György Haskó
Journal:  FASEB J       Date:  2014-10-15       Impact factor: 5.191

Review 7.  Adenosinergic signaling as a target for natural killer cell immunotherapy.

Authors:  Jiao Wang; Sandro Matosevic
Journal:  J Mol Med (Berl)       Date:  2018-08-01       Impact factor: 4.599

Review 8.  Regulation of the T Cell Response by CD39.

Authors:  Maisa C Takenaka; Simon Robson; Francisco J Quintana
Journal:  Trends Immunol       Date:  2016-05-25       Impact factor: 16.687

9.  Modulation of CD39 and Exogenous APT102 Correct Immune Dysfunction in Experimental Colitis and Crohn's Disease.

Authors:  René J Robles; Samiran Mukherjee; Marta Vuerich; Anyan Xie; Rasika Harshe; Peter J Cowan; Eva Csizmadia; Yan Wu; Alan C Moss; Ridong Chen; Simon C Robson; Maria Serena Longhi
Journal:  J Crohns Colitis       Date:  2020-07-09       Impact factor: 9.071

10.  Adenosine modulates Toll-like receptor function: basic mechanisms and translational opportunities.

Authors:  Melanie R Power Coombs; Mirjam E Belderbos; Leighanne C Gallington; Louis Bont; Ofer Levy
Journal:  Expert Rev Anti Infect Ther       Date:  2011-02       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.